Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma

Abstract

TLX contributes to glioma malignancy and immunosuppression through transcriptional activation of PD-L1 ligands that bind to PD-1 expressed on both TILs and TAMs. Thus, targeting the druggable TLX may have potential therapeutic significance in glioma immune therapy.